胆管癌化疗之外：深入剖析TOPAZ-1试验的最新长期随访数据 - Suppr

Beyond chemotherapy in biliary tract cancer: a closer look at the updated long-term follow-up data of the TOPAZ-1 trial.

作者信息

Olkus Alexander, Dill Michael T

机构信息

Heidelberg Faculty of Medicine, Heidelberg University, Heidelberg, Germany.

Department of Gastroenterology, Hepatology, Infectious Diseases and Intoxications, Heidelberg University Hospital, Heidelberg, Germany.

出版信息

Hepatobiliary Surg Nutr. 2025 Aug 1;14(4):676-679. doi: 10.21037/hbsn-2025-316. Epub 2025 Jul 25.

DOI:10.21037/hbsn-2025-316

PMID:40893741

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12393116/

Abstract

摘要

相似文献

Beyond chemotherapy in biliary tract cancer: a closer look at the updated long-term follow-up data of the TOPAZ-1 trial.

Hepatobiliary Surg Nutr. 2025 Aug 1;14(4):676-679. doi: 10.21037/hbsn-2025-316. Epub 2025 Jul 25.

Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study.

Lancet Gastroenterol Hepatol. 2024 Aug;9(8):694-704. doi: 10.1016/S2468-1253(24)00095-5. Epub 2024 May 29.

Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study.

J Hepatol. 2025 May 15. doi: 10.1016/j.jhep.2025.05.003.

Prognostic impact of neutrophil-to-lymphocyte ratio (NLR) in patients with unresectable biliary tract cancer treated with gemcitabine, cisplatin, and durvalumab.

World J Surg Oncol. 2025 Jul 1;23(1):258. doi: 10.1186/s12957-025-03834-x.

Real-world effectiveness and prognostic factors of durvalumab plus chemotherapy in a multicentric cohort with advanced biliary tract cancer.

Oncologist. 2025 Aug 4;30(8). doi: 10.1093/oncolo/oyae306.

Postoperative adjuvant chemotherapy and chemoimmunotherapy after radical resection for biliary tract cancer: a retrospective study.

Oncologist. 2025 Jun 4;30(6). doi: 10.1093/oncolo/oyaf163.

Targeting PD-1/PD-L1 in biliary tract cancer: role and available data.

Immunotherapy. 2023 May;15(7):517-530. doi: 10.2217/imt-2022-0190. Epub 2023 Apr 3.

ABC-12: exploring the microbiome in patients with advanced biliary tract cancer in a first-line study of durvalumab (MEDI4736) in combination with cisplatin/gemcitabine.

Future Oncol. 2025 Jul 29:1-9. doi: 10.1080/14796694.2025.2539018.

Survival Outcomes of Durvalumab in Combination with Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer: Real-World Results from a Single Italian Institution.

Oncology. 2025;103(8):677-698. doi: 10.1159/000541891. Epub 2024 Dec 6.

Associations between reproductive factors and biliary tract cancers in women from the Biliary Tract Cancers Pooling Project.

J Hepatol. 2020 Oct;73(4):863-872. doi: 10.1016/j.jhep.2020.04.046. Epub 2020 May 11.

本文引用的文献

Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study.

J Hepatol. 2025 May 15. doi: 10.1016/j.jhep.2025.05.003.

Efficacy, safety and differential outcomes of immune-chemotherapy with gemcitabine, cisplatin and durvalumab in patients with biliary tract cancers: A multicenter real world cohort.

United European Gastroenterol J. 2024 Nov;12(9):1230-1242. doi: 10.1002/ueg2.12656. Epub 2024 Sep 20.

Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study.

Lancet Gastroenterol Hepatol. 2024 Aug;9(8):694-704. doi: 10.1016/S2468-1253(24)00095-5. Epub 2024 May 29.

Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial.

Lancet Oncol. 2024 May;25(5):626-635. doi: 10.1016/S1470-2045(24)00082-2.

Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: An Exploratory Analysis of Real-World Data.

Target Oncol. 2024 Mar;19(2):213-221. doi: 10.1007/s11523-024-01044-1. Epub 2024 Feb 28.

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.

NEJM Evid. 2022 Aug;1(8):EVIDoa2200015. doi: 10.1056/EVIDoa2200015. Epub 2022 Jun 1.

Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data.

Liver Int. 2023 Aug;43(8):1803-1812. doi: 10.1111/liv.15641.

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.

Lancet. 2023 Jun 3;401(10391):1853-1865. doi: 10.1016/S0140-6736(23)00727-4. Epub 2023 Apr 16.

Intensive Follow-Up Program and Oncological Outcomes of Biliary Tract Cancer Patients after Curative-Intent Surgery: A Twenty-Year Experience in a Single Tertiary Medical Center.

Curr Oncol. 2022 Jul 19;29(7):5084-5090. doi: 10.3390/curroncol29070402.

Biliary tract cancer.

Lancet. 2021 Jan 30;397(10272):428-444. doi: 10.1016/S0140-6736(21)00153-7.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Beyond chemotherapy in biliary tract cancer: a closer look at the updated long-term follow-up data of the TOPAZ-1 trial.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

本文引用的文献